- In February 2023, the European Medicines Agency (EMA) issued guidelines aimed at improving the clinical development of therapies for rare endocrine disorders, including Addison’s disease. These included considerations for innovative delivery routes and long-acting corticosteroids.
- The industry is witnessing a growing trend toward the development of personalized hormone replacement therapies, emphasis on adrenal-specific biomarkers, and increased use of digital platforms for patient monitoring. Additionally, there is a strong focus on improving drug adherence and reducing side effects through modified-release and dual-release formulations.
